Fabry Disease, Cardiac Variant Clinical Trials
3 recruiting trials for Fabry Disease, Cardiac Variant. Eligibility criteria explained in plain English.
TrialFinderData lists 3 Fabry Disease, Cardiac Variant clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by China National Center for Cardiovascular Diseases (1), University of Cambridge (1), Wuerzburg University Hospital (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is 68Ga-DOTATATE PET/MRI (diagnostic_test, 1 trial).
Track Fabry Disease, Cardiac Variant trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
CVI Alterations in FD: a Prospective, Multicenter, Observational Cohort Study
Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by α-galactosidase A (GLA) gene mutations leading to reduced or undetectable α galactosidase A (α-Gal A)...
Molecular Imaging in Fabry Disease of the Heart
Better methods for early detection of cardiac involvement in Fabry disease are needed to inform clinical management decisions that can help prevent or slow the progression of...
Evaluation of HEArt invoLvement in Patients With FABRY Disease
This study evaluates predictors for the incidence of arrhythmias and sudden cardiac death as well as terminal heart failure in patients with Fabry disease.
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Fabry Disease, Cardiac Variant, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Fabry Disease, Cardiac Variant, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Fabry Disease, Cardiac Variant, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.